Importantly, AREG overexpression has been identified as a key mechanism underlying resistance to EGFR inhibitors such as gefitinib in non-small-cell lung cancer and other cancer types [42,182,184]. The gene discussed is AREG; the disease is non-small cell lung carcinoma.